Procept BioRobotics Corp (PRCT) concluded trading on Thursday at a closing price of $52.56, with 2.97 million shares of worth about $156.0 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -22.93% during that period and on April 24, 2025 the price saw a loss of about -5.64%. Currently the company’s common shares owned by public are about 54.72M shares, out of which, 51.88M shares are available for trading.
Stock saw a price change of -0.47% in past 5 days and over the past one month there was a price change of -15.94%. Year-to-date (YTD), PRCT shares are showing a performance of -34.72% which increased to 2.68% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $47.04 but also hit the highest price of $103.81 during that period. The average intraday trading volume for Procept BioRobotics Corp shares is 989.13K. The stock is currently trading -3.12% below its 20-day simple moving average (SMA20), while that difference is down -10.86% for SMA50 and it goes to -28.48% lower than SMA200.
Procept BioRobotics Corp (NASDAQ: PRCT) currently have 54.72M outstanding shares and institutions hold larger chunk of about 92.23% of that.
The stock has a current market capitalization of $2.88B and its 3Y-monthly beta is at 1.09. It has posted earnings per share of -$1.76 in the same period. It has Quick Ratio of 8.01 while making debt-to-equity ratio of 0.20. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PRCT, volatility over the week remained 6.03% while standing at 6.74% over the month.
Stock’s fiscal year EPS is expected to rise by 14.13% while it is estimated to increase by 33.76% in next year. EPS is likely to grow at an annualized rate of 35.74% for next 5-years, compared to annual growth of -12.56% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on December 02, 2024 offering an Overweight rating for the stock and assigned a target price of $105 to it. Coverage by Jefferies stated Procept BioRobotics Corp (PRCT) stock as a Hold in their note to investors on November 14, 2024, suggesting a price target of $95 for the stock. Stock get a Neutral rating from BTIG Research on October 31, 2022.
